AU2014220735B2 - Vortioxetine manufacturing process - Google Patents

Vortioxetine manufacturing process Download PDF

Info

Publication number
AU2014220735B2
AU2014220735B2 AU2014220735A AU2014220735A AU2014220735B2 AU 2014220735 B2 AU2014220735 B2 AU 2014220735B2 AU 2014220735 A AU2014220735 A AU 2014220735A AU 2014220735 A AU2014220735 A AU 2014220735A AU 2014220735 B2 AU2014220735 B2 AU 2014220735B2
Authority
AU
Australia
Prior art keywords
compound
formula
piperazine
process according
equivalents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014220735A
Other languages
English (en)
Other versions
AU2014220735A1 (en
Inventor
Kim Lasse Christensen
Thomas Ruhland
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2014220735A1 publication Critical patent/AU2014220735A1/en
Application granted granted Critical
Publication of AU2014220735B2 publication Critical patent/AU2014220735B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/02Iron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
AU2014220735A 2013-02-22 2014-02-20 Vortioxetine manufacturing process Active AU2014220735B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361767883P 2013-02-22 2013-02-22
DKPA201300104 2013-02-22
DKPA201300104 2013-02-22
PCT/EP2014/053313 WO2014128207A1 (en) 2013-02-22 2014-02-20 Vortioxetine manufacturing process

Publications (2)

Publication Number Publication Date
AU2014220735A1 AU2014220735A1 (en) 2015-08-20
AU2014220735B2 true AU2014220735B2 (en) 2017-06-22

Family

ID=59215387

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014220735A Active AU2014220735B2 (en) 2013-02-22 2014-02-20 Vortioxetine manufacturing process

Country Status (37)

Country Link
US (1) US9353073B2 (enExample)
EP (1) EP2958903B1 (enExample)
JP (1) JP6464098B2 (enExample)
KR (1) KR102230628B1 (enExample)
CN (1) CN104995181B (enExample)
AP (1) AP2015008640A0 (enExample)
AU (1) AU2014220735B2 (enExample)
BR (1) BR112015019268B1 (enExample)
CA (1) CA2901821A1 (enExample)
CL (1) CL2015002309A1 (enExample)
CR (1) CR20150423A (enExample)
CY (1) CY1118883T1 (enExample)
DK (1) DK2958903T3 (enExample)
DO (1) DOP2015000187A (enExample)
EA (1) EA027756B1 (enExample)
ES (1) ES2625380T3 (enExample)
GE (1) GEP201706749B (enExample)
HR (1) HRP20170607T1 (enExample)
IL (1) IL240501B (enExample)
LT (1) LT2958903T (enExample)
MA (1) MA38338B1 (enExample)
ME (1) ME02671B (enExample)
MX (1) MX362355B (enExample)
MY (1) MY172337A (enExample)
PE (1) PE20151589A1 (enExample)
PH (1) PH12015501807B1 (enExample)
PL (1) PL2958903T3 (enExample)
PT (1) PT2958903T (enExample)
RS (1) RS55932B1 (enExample)
RU (1) RU2652265C2 (enExample)
SG (1) SG11201506651SA (enExample)
SI (1) SI2958903T1 (enExample)
SM (1) SMT201700238T1 (enExample)
TN (1) TN2015000335A1 (enExample)
UA (1) UA116236C2 (enExample)
WO (1) WO2014128207A1 (enExample)
ZA (1) ZA201506050B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2605652B1 (en) 2010-08-18 2017-11-08 Samumed, LLC Diketones and hydroxyketones as catenin signaling pathway activators
ES2709824T3 (es) 2013-02-22 2019-04-17 Samumed Llc Gamma-dicetonas como activadores de la ruta de señalización Wnt/beta-catenina
DK3206686T3 (da) 2014-08-20 2019-12-16 Samumed Llc Gamma-diketoner til behandling og forebyggelse af ældning af huden og rynker
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
EP3274330A1 (en) 2015-03-26 2018-01-31 Cipla Limited Method for making serotonin reuptake inhibitors
CN106279065A (zh) * 2015-05-12 2017-01-04 北京深蓝海生物医药科技有限公司 一种氢溴酸沃替西汀的精制转晶方法
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
EP3414216B1 (en) * 2016-02-08 2020-10-21 AAA Chemistry ApS Arylation of aliphatic amines
JP2019524682A (ja) 2016-07-01 2019-09-05 ハー・ルンドベック・アクチエゼルスカベット 抗うつ作用の速い発現のためのボルチオキセチン投与計画
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN109912538B (zh) * 2019-01-22 2021-03-12 安徽赛乐普制药有限公司 一种抗抑郁药沃替西汀的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029232A1 (en) * 2001-10-04 2003-04-10 H. Lundbeck A/S Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005989A (es) * 2001-12-20 2004-09-27 Lundbeck & Co As H Derivados de ariloxifenilo y arilsulfanilfenilo.
KR20090028712A (ko) * 2006-06-16 2009-03-19 하. 룬트벡 아크티에 셀스카브 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진
TW201033181A (en) * 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003029232A1 (en) * 2001-10-04 2003-04-10 H. Lundbeck A/S Phenyl-piperazine derivatives as serotonin reuptake inhibitors

Also Published As

Publication number Publication date
RU2015134407A (ru) 2017-03-28
IL240501B (en) 2018-08-30
IL240501A0 (en) 2015-09-24
EA201591349A1 (ru) 2015-12-30
PE20151589A1 (es) 2015-12-03
PL2958903T3 (pl) 2017-08-31
RU2652265C2 (ru) 2018-04-27
WO2014128207A1 (en) 2014-08-28
SMT201700238T1 (it) 2017-07-18
MX362355B (es) 2019-01-14
HK1216098A1 (en) 2016-10-14
CL2015002309A1 (es) 2016-03-04
CR20150423A (es) 2015-10-20
US20160009670A1 (en) 2016-01-14
ES2625380T3 (es) 2017-07-19
CN104995181B (zh) 2017-03-08
PH12015501807B1 (en) 2019-05-31
MY172337A (en) 2019-11-21
US9353073B2 (en) 2016-05-31
EP2958903A1 (en) 2015-12-30
ME02671B (me) 2017-06-20
JP2016509042A (ja) 2016-03-24
BR112015019268B1 (pt) 2023-01-10
LT2958903T (lt) 2017-08-25
MX2015010656A (es) 2015-12-17
AU2014220735A1 (en) 2015-08-20
DOP2015000187A (es) 2015-11-30
HRP20170607T1 (hr) 2017-06-30
EA027756B1 (ru) 2017-08-31
PT2958903T (pt) 2017-05-26
RS55932B1 (sr) 2017-09-29
AP2015008640A0 (en) 2015-08-31
CN104995181A (zh) 2015-10-21
EP2958903B1 (en) 2017-04-12
DK2958903T3 (en) 2017-05-15
MA38338A1 (fr) 2016-09-30
KR20150118146A (ko) 2015-10-21
TN2015000335A1 (en) 2017-01-03
SI2958903T1 (sl) 2017-09-29
SG11201506651SA (en) 2015-09-29
JP6464098B2 (ja) 2019-02-06
MA38338B1 (fr) 2018-10-31
GEP201706749B (en) 2017-10-10
CY1118883T1 (el) 2018-01-10
BR112015019268A2 (pt) 2020-01-28
KR102230628B1 (ko) 2021-03-22
UA116236C2 (uk) 2018-02-26
ZA201506050B (en) 2017-08-30
CA2901821A1 (en) 2014-08-28
PH12015501807A1 (en) 2015-11-09

Similar Documents

Publication Publication Date Title
AU2014220735B2 (en) Vortioxetine manufacturing process
CN104011034B (zh) 用于生产1-[2-(2,4-二甲基-苯基硫烷基)-苯基]-哌嗪的方法
JP6451652B2 (ja) (r)−1,1,3−トリメチル−4−アミノインダンの製造方法
Yin et al. Solvent-free copper-catalyzed N-arylation of amino alcohols and diamines with aryl halides
KR20220051168A (ko) 헤테로시클리덴아세트아미드 유도체의 제조 방법
CN105348220B (zh) 一种氢溴酸沃替西汀的合成方法
CN104628676A (zh) 一种Vortioxetine的制备方法
JP2014524438A (ja) インデノピリジン誘導体
HK1216098B (en) Vortioxetine manufacturing process
OA17454A (en) Vortioxetine manufacturing process.
NZ710779A (en) Vortioxetine manufacturing process
NZ710779B2 (en) Vortioxetine manufacturing process
JP2025083072A (ja) ボルチオキセチンの製造方法
JP5439745B2 (ja) ハロゲノメチルペンタフルオロスルファニルベンゼン化合物及びその製造方法
TW201825463A (zh) 用於製備1-(4-(2-((1-(3,4-二氟苯基)-1h-吡唑-3-基)甲氧基)乙基)哌-1-基)乙酮的方法和中間體
JP2011207844A (ja) ビベンゾイミダゾール化合物の製造方法
JP2022506577A (ja) D3ドーパミン受容体アゴニストを合成する方法
JP2007070300A (ja) 2,5−ジアミノ−1,4−ベンゾキノン及び2,5−ジアミノ−1,4−ベンゼンジオール、およびその塩の製造方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE PRIORITY DETAILS TO READ PA201300104 22 FEB 2013 DK

FGA Letters patent sealed or granted (standard patent)